[go: up one dir, main page]

WO2004087044A3 - Drug target - Google Patents

Drug target Download PDF

Info

Publication number
WO2004087044A3
WO2004087044A3 PCT/US2003/040752 US0340752W WO2004087044A3 WO 2004087044 A3 WO2004087044 A3 WO 2004087044A3 US 0340752 W US0340752 W US 0340752W WO 2004087044 A3 WO2004087044 A3 WO 2004087044A3
Authority
WO
WIPO (PCT)
Prior art keywords
drug target
monitoring
genes
useful
ifit1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/040752
Other languages
French (fr)
Other versions
WO2004087044A2 (en
Inventor
Ivan Plavec
Oksana Sirenko
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioseek LLC
Original Assignee
Bioseek LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioseek LLC filed Critical Bioseek LLC
Priority to AU2003303963A priority Critical patent/AU2003303963A1/en
Publication of WO2004087044A2 publication Critical patent/WO2004087044A2/en
Publication of WO2004087044A3 publication Critical patent/WO2004087044A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Assays and screens for monitoring the expression of genes involved in the inflammatory response, such as the IFIT1, and for monitoring the activity of the products of such genes are useful in the identification of agents useful in the treatment of inflammatory disease.
PCT/US2003/040752 2002-12-20 2003-12-19 Drug target Ceased WO2004087044A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003303963A AU2003303963A1 (en) 2002-12-20 2003-12-19 Drug target

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43584802P 2002-12-20 2002-12-20
US60/435,848 2002-12-20

Publications (2)

Publication Number Publication Date
WO2004087044A2 WO2004087044A2 (en) 2004-10-14
WO2004087044A3 true WO2004087044A3 (en) 2005-02-17

Family

ID=33131511

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/040752 Ceased WO2004087044A2 (en) 2002-12-20 2003-12-19 Drug target

Country Status (2)

Country Link
AU (1) AU2003303963A1 (en)
WO (1) WO2004087044A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2647669A1 (en) * 2005-03-28 2006-10-05 Bioseek, Inc. Biological dataset profiling of cardiovascular disease and cardiovascular inflammation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5599669A (en) * 1990-10-16 1997-02-04 The Regents Of The University Of Michigan Cytokine-induced marker for inflammatory response
WO2002002807A2 (en) * 2000-06-30 2002-01-10 Epigenomics Ag Diagnosis of diseases associated with cell signalling

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5599669A (en) * 1990-10-16 1997-02-04 The Regents Of The University Of Michigan Cytokine-induced marker for inflammatory response
WO2002002807A2 (en) * 2000-06-30 2002-01-10 Epigenomics Ag Diagnosis of diseases associated with cell signalling

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ALBANESI ET AL: "Cetirizine and hydrocortisone differentially regulate ICAM-1 expression and chemokine release in cultured human keratinocytes", CLINICAL AND EXPERIMENTAL ALLERGY, vol. 28, 1998, pages 101 - 109, XP002982198 *
FESSLER ET AL: "A genomic and proteomic analysis of activation of the human neutrophil by lipopolysaccharide and its mediation by p38 mitogen-activated protein kinase", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 277, no. 35, 30 August 2002 (2002-08-30), pages 31291 - 31302, XP002982197 *

Also Published As

Publication number Publication date
AU2003303963A8 (en) 2004-10-25
WO2004087044A2 (en) 2004-10-14
AU2003303963A1 (en) 2004-10-25

Similar Documents

Publication Publication Date Title
EP1929073A4 (en) PROTEIN PHARMACEUTICAL PRODUCTS AND USES THEREOF
TWI347844B (en) Sulfoximine-substituted pyrimidines as cdk-and/or vegf inhibitors, their production and use as pharmaceutical agents
NL1026892A1 (en) 11.8 Naphthyridin-2-ones and related compounds for the treatment of schizophrenia.
WO2004009062A3 (en) NMDA RECEPTOR ANTAGONISTS AND THEIR USE IN INHIBITING ABNORMAL HYPERPHOSPHORYLATION OF MICROTUBULE ASSOCIATED PROTEIN tau
WO2004011611A3 (en) Taci antibodies and uses thereof
TWI347201B (en) Pharmaceutical products,uses thereof and methods for preparing the same
AP2004003184A0 (en) Benzofused heteroaryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same and methods for their use.
WO2004113277A3 (en) Methods and compositions for treating amyloid-related diseases
ITTO20021009A1 (en) PROCEDURE, SYSTEM AND IT PRODUCT FOR THE
WO2004006858A3 (en) Compounds, compositions, and methods employing same
PL375790A1 (en) Novel fluoroglycoside heterocyclic derivatives, pharmaceutical products containing said compounds and the use thereof
WO2005016227A3 (en) Methods and pharmaceutical compositions for modulating heparanase activation and uses thereof
ATE418967T2 (en) MATRIX FOR THE MODIFIED RELEASE OF ACTIVE SUBSTANCES
ATE524178T1 (en) ACYLATED HETEROARYL-CONDENSED CYCLOALKENYLAMINES AND THEIR USE AS MEDICINAL PRODUCTS
FR2840903B1 (en) GLUCOSE AND VITAMIN F DERIVATIVE, COMPOSITIONS COMPRISING THE SAME, AND USES FOR IMPROVING THE CONDITION OF HAIR AND HAIR
PA8583601A1 (en) PIRROLIDONE DERIVATIVES AS MAOB INHIBITORS
WO2004071382A3 (en) Substituted heterocycles
EG24784A (en) Isoindolone derivatives, preparation process and intermediates of this process, their use as medicaments and pharmaceutical comprising them.
EP1506965A4 (en) PROPANOLAMINE DERIVATIVES, PROCESS FOR THE PREPARATION OF 3-N-METHYLAMINO-1- (2-THIENYL) -1-PROPANOLS AND PROCESS FOR THE PREPARATION OF PROPANOLAMINE DERIVATIVES
NL1024676A1 (en) HIV integrase inhibitors, pharmaceutical preparations and methods for their use.
IL163951A (en) Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them
WO2010019914A3 (en) Anti-arrhythmia agents, methods of their use, methods for their identification, and kits thereofre
EP1961764A4 (en) SUGAR CHAIN AND PEPTIDE ADDITION PRODUCT AND PHARMACEUTICAL PRODUCT COMPRISING SAID PRODUCT AS ACTIVE INGREDIENT
DE60320811D1 (en) SETTING, PLASTISOL COMPOSITION AND PRODUCT AND FORMKOERPER THEREOF
ATE424823T1 (en) 4-PHENYL-5-OXO-1,4,5,6,7,8-HEXAHYDROCINOLINE DERIVATIVES AS MEDICINAL PRODUCTS FOR THE TREATMENT OF INFERTILITY

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP